Mingde Biology: From April 22, trading will resume with a delisting risk warning, and the abbreviation will be changed to *ST Mingde.

Mingde Biology Announcement: The company’s stock was suspended for one day on April 21. Starting from April 22, delisting risk warning measures were implemented. The stock abbreviation was changed from “Mingde Biology” to “*ST Mingde,” and the daily limit for price fluctuations is 5%. According to the company’s “2025 Annual Report,” in 2025 the company had a total profit of a loss of 63.794 million yuan, net profit attributable to shareholders of the listed company of a loss of 16.4607 million yuan, and net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses of a loss of 117 million yuan. Operating revenue was 265 million yuan, and operating revenue after deductions was 241 million yuan. According to relevant regulations, because the company’s financial indicators for 2025 fall under the situation that “the lowest of the audited total profit, net profit, and net profit after deducting non-recurring gains and losses for the most recent accounting year is negative, and the operating revenue after deductions is less than 300 million yuan,” the Shenzhen Stock Exchange has imposed a delisting risk warning on the company’s stock. If the company experiences the above situation in 2026, the Shenzhen Stock Exchange will decide to terminate the listing of the company’s stock.